HemaCare Corp. (HemaCare) operates in two segments: blood products and therapeutic services. The blood products segment includes the sale of apheresis platelets on an exclusive basis to The American National Red Cross (ARC), and sales of other blood products to research, cellular therapy and other health and biotech related organizations. In the therapeutic services segment, the Company performs therapeutic apheresis procedures, stem cell collection, and other blood treatments on patients with a variety of disorders. Therapeutic services are provided under contract with hospitals as an outside purchased service. In October 2013, HemaCare Corp. completed the sale of its Coral Blood Services subsidiary to the New York Blood Center (NYBC).